Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection

Exebacase (CF-301) is a novel antistaphylococcal lysin (cell wall hydrolase) in phase 3 of clinical development for the treatment of Staphylococcus aureus bacteremia, including right-sided endocarditis, used in addition to standard-of-care antibiotics. In the current study, the potential for exebaca...

Descripción completa

Detalles Bibliográficos
Autores principales: Swift, Steven M., Sauve, Karen, Cassino, Cara, Schuch, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370210/
https://www.ncbi.nlm.nih.gov/pubmed/34228536
http://dx.doi.org/10.1128/AAC.02723-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370210/
https://www.ncbi.nlm.nih.gov/pubmed/34228536
http://dx.doi.org/10.1128/AAC.02723-20

Ejemplares similares